Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus rating of “Hold” from the eighteen brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.61.
NVO has been the subject of several analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 29th. They issued an “outperform” rating for the company. Barclays reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 5th. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Monday, April 29th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Friday, February 1st. They set an “equal weight” rating for the company. Finally, Handelsbanken downgraded shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price objective for the company. in a report on Monday, February 4th.
Shares of NYSE:NVO opened at $47.00 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The firm has a market capitalization of $115.75 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.12 and a beta of 0.56.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
See Also: Futures Contract
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.